DelveInsight’s “Gastroenteropancreatic Neuroendocrine Tumor Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Gastroenteropancreatic Neuroendocrine Tumor, historical and forecasted epidemiology as well as the Gastroenteropancreatic Neuroendocrine Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Get a Free sample for the Gastroenteropancreatic Neuroendocrine Tumor Market Report:
https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market
Some of the key facts of the Gastroenteropancreatic Neuroendocrine Tumor Market Report:
The Gastroenteropancreatic Neuroendocrine Tumor market size is anticipated to grow with a significant CAGR during the study period (2022-2036).
According to the Camurus AB’s 2026 presentation, results from the Phase III (SORENTO) trial are expected to be presented in 2026.
In November 2025, ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the company’s New Drug Application (NDA) for n.c.a. 177Lu-edotreotide (also known as ITM-11 or 177Lu-edotreotide). This proprietary, synthetic, targeted radiotherapeutic investigational agent is being developed by ITM for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The FDA has established a Prescription Drug User Fee Act (PDUFA) target action date of August 28, 2026.
In March 2025, US FDA approved cabozantinib (CABOMETYX, RayzeBio, Inc.) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
Radioligand therapies and targeted agents are expected to remain key drivers of market expansion.
Emerging pipeline candidates focusing on receptor targeting, angiogenesis, and combination approaches such as surufatinib, and 177Lu-edotreotide are anticipated to increase competition and shape future treatment strategies.
The US contributed to the highest incident cases of NETs. The total incident cases of NETs in the United States in 2025 were 31,000.
According to the secondary search, net project, the incidence of malignant GEP-NET during 2000–2007 was 1.7 per 100,000 population per year in Europe, corresponding to an estimated 26,000 new cases.
As per the secondary sesrch, the annual incidence of the disease was 6.47 cases per 100,000 population, with an adjusted prevalence of 0.052%. The mean age at diagnosis was 58 ± 15 years, and the gender distribution was nearly equal, with 51% men and 49% women in Spain.
Surgical resection of the primary tumor was performed in 66% of patients. Histopathological grading showed that most tumors were well differentiated, with 73% classified as Grade 1 (G1), 22% as Grade 2 (G2), and 5% as Grade 3 (G3).
The most common primary tumor site was the pancreas (52%), followed by the jejunum–ileum (23%). At the time of diagnosis, 24% of patients presented with distant metastases, most frequently involving the liver (44%), peritoneum (25%), or multiple organs (22%). The majority of tumors were sporadic and non-functional.
Key Gastroenteropancreatic Neuroendocrine Tumor Companies: ITM Isotope Technologies Munich, Camurus, RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator, Jiangsu HengRui Medicine, Camurus AB, Novartis, Tarveda Therapeutics, Progenics Pharmaceuticals, Pharmacyclics, and others
Key Gastroenteropancreatic Neuroendocrine Tumor Therapies: SOMATULINE DEPOT, ITM-11, CAM2029, RYZ101, Lanreotide, arginine, lysine, Temozolomide (TMZ), Lutetium (177Lu) Oxodotreotide Injection, CAM2029, Everolimus, PEN-221, Lutathera, Ibrutinib, and others
The Gastroenteropancreatic Neuroendocrine Tumor epidemiology based on gender analyzed that the incidence of functional GEP-NET is more than that of nonfunctional GEP-NET in the United States
The Gastroenteropancreatic Neuroendocrine Tumor market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroenteropancreatic Neuroendocrine Tumor pipeline products will significantly revolutionize the Gastroenteropancreatic Neuroendocrine Tumor market dynamics.
Gastroenteropancreatic Neuroendocrine Tumor Overview
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) are a diverse group of tumors that arise from neuroendocrine cells in the gastrointestinal (GI) tract and pancreas. These cells have both endocrine and neural characteristics and are responsible for producing hormones that regulate various physiological functions.
To Know in detail about the Gastroenteropancreatic Neuroendocrine Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GEP-NETs Market Forecast
Gastroenteropancreatic Neuroendocrine Tumor Epidemiology
The Gastroenteropancreatic Neuroendocrine Tumor epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Gastroenteropancreatic Neuroendocrine Tumor Epidemiology Segmentation:
The Gastroenteropancreatic Neuroendocrine Tumor market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:
Total Incident Cases of GEP-NET in the 7MM
Grade-Specific Cases of GEP-NET in the 7MM
Tumor site-specific Cases of GEP-NET in the 7MM
Stage-specific Cases of GEP-NET in the 7MM
Symptom-specific Cases of GEP-NET in the 7MM
Download the report to understand which factors are driving GEP-NETs epidemiology trends @ Gastroenteropancreatic Neuroendocrine Tumor Epidemiology Forecast
Gastroenteropancreatic Neuroendocrine Tumor Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroenteropancreatic Neuroendocrine Tumor market or expected to get launched during the study period. The analysis covers Gastroenteropancreatic Neuroendocrine Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Gastroenteropancreatic Neuroendocrine Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Gastroenteropancreatic Neuroendocrine Tumor Therapies and Key Companies
LUTATHERA (lutetium Lu 177 DOTATATE): Novartis
ITM-11 (n.c.a. 177Lu-edotreotide): ITM Isotope Technologies Munich
SOMATULINE DEPOT: Ipsen Biopharmaceuticals
ITM-11: ITM Isotope Technologies Munich
CAM2029: Camurus
RYZ101: RayzeBio
Lanreotide: Merck Sharp & Dohme
arginine/lysine: Advanced Accelerator
Temozolomide (TMZ): Ipsen
Lutetium (177Lu) Oxodotreotide Injection: Jiangsu HengRui Medicine
RYZ101: RayzeBio, Inc.
CAM2029: Camurus AB
Everolimus: Novartis
PEN-221: Tarveda Therapeutics
Lutathera: Progenics Pharmaceuticals
Ibrutinib: Pharmacyclics
Discover more about therapies set to grab major GEP-NETs market share @ Gastroenteropancreatic Neuroendocrine Tumor Treatment Market
Gastroenteropancreatic Neuroendocrine Tumor Market Strengths
GEP-NETs are often diagnosed at an early stage due to the hormonal symptoms they produce, allowing for timely intervention and better outcomes.
Treatment of GEP-NETs involves a multidisciplinary team of specialists, including oncologists, surgeons, and endocrinologists, which enhances the overall management of the disease.
Gastroenteropancreatic Neuroendocrine Tumor Market Opportunities
Continued research and development in targeted therapies, such as somatostatin analogs and molecular inhibitors, provide opportunities for more effective and personalized treatment approaches.
Participation in clinical trials can lead to the discovery of new treatment modalities and contribute to the improvement of patient outcomes.
Scope of the Gastroenteropancreatic Neuroendocrine Tumor Market Report
Study Period: 2022–2036
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Gastroenteropancreatic Neuroendocrine Tumor Therapeutic Assessment: Gastroenteropancreatic Neuroendocrine Tumor current marketed and Gastroenteropancreatic Neuroendocrine Tumor emerging therapies
Gastroenteropancreatic Neuroendocrine Tumor Market Dynamics: Gastroenteropancreatic Neuroendocrine Tumor market drivers and Gastroenteropancreatic Neuroendocrine Tumor market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Gastroenteropancreatic Neuroendocrine Tumor Unmet Needs, KOL’s views, Analyst’s views, Gastroenteropancreatic Neuroendocrine Tumor Market Access and Reimbursement
To know more about GEP-NETs companies working in the treatment market, visit @ Gastroenteropancreatic Neuroendocrine Tumor Clinical Trials and Therapeutic Assessment
Table of Contents
1. Gastroenteropancreatic Neuroendocrine Tumor Market Report Introduction
2. Executive Summary for Gastroenteropancreatic Neuroendocrine Tumor
3. SWOT analysis of Gastroenteropancreatic Neuroendocrine Tumor
4. Gastroenteropancreatic Neuroendocrine Tumor Patient Share (%) Overview at a Glance
5. Gastroenteropancreatic Neuroendocrine Tumor Market Overview at a Glance
6. Gastroenteropancreatic Neuroendocrine Tumor Disease Background and Overview
7. Gastroenteropancreatic Neuroendocrine Tumor Epidemiology and Patient Population
8. Country-Specific Patient Population of Gastroenteropancreatic Neuroendocrine Tumor
9. Gastroenteropancreatic Neuroendocrine Tumor Current Treatment and Medical Practices
10. Gastroenteropancreatic Neuroendocrine Tumor Unmet Needs
11. Gastroenteropancreatic Neuroendocrine Tumor Emerging Therapies
12. Gastroenteropancreatic Neuroendocrine Tumor Market Outlook
13. Country-Wise Gastroenteropancreatic Neuroendocrine Tumor Market Analysis (2022–2036)
14. Gastroenteropancreatic Neuroendocrine Tumor Market Access and Reimbursement of Therapies
15. Gastroenteropancreatic Neuroendocrine Tumor Market Drivers
16. Gastroenteropancreatic Neuroendocrine Tumor Market Barriers
17. Gastroenteropancreatic Neuroendocrine Tumor Appendix
18. Gastroenteropancreatic Neuroendocrine Tumor Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679 Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
